Wu Lichuan, Wang Guizhen, Wei Jinrui, Huang Na, Zhang Sen, Yang Fangfang, Li Ming, Zhou Guangbiao, Wang Lisheng
School of Chemistry and Chemical Engineering, Guangxi University, Nanning, Guangxi, PR China.
State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, PR China.
Oncotarget. 2017 Feb 14;8(7):11729-11738. doi: 10.18632/oncotarget.14329.
Lung cancer is the leading cause of cancer related death which needs novel drugs to improve patient outcomes. In this study, we examined the ability of YF-18, a novel matrine derivative to inhibit the growth and migration of lung cancer cells. By cell cycle analysis, wound healing and transwell assays, we found that YF-18 induced G2/M cell cycle arrest and inhibited migration of lung cancer cells in a dose-dependent manner. Further results indicated that YF-18 inhibited cell proliferation and migration through down-regulating Skp2 and up-regulating its substrates, p27 and E-cadherin. Moreover, YF-18 inhibited A549-luciferase cell xenograft tumor growth in a dose-dependent manner. The findings indicate that YF-18 bears therapeutic potentials for lung cancer.
肺癌是癌症相关死亡的主要原因,需要新型药物来改善患者预后。在本研究中,我们检测了新型苦参碱衍生物YF-18抑制肺癌细胞生长和迁移的能力。通过细胞周期分析、伤口愈合实验和Transwell实验,我们发现YF-18以剂量依赖的方式诱导G2/M期细胞周期阻滞并抑制肺癌细胞的迁移。进一步的结果表明,YF-18通过下调Skp2并上调其底物p27和E-钙黏蛋白来抑制细胞增殖和迁移。此外,YF-18以剂量依赖的方式抑制A549-荧光素酶细胞异种移植瘤的生长。这些发现表明YF-18对肺癌具有治疗潜力。